Target Gene/Pathway Pathway / Gene

  

Search results

No. KEGG GENES KEGG PATHWAY KEGG DRUG DrugBank Disease ID
1 DDC [7] Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Cocaine addiction D00558 Carbidopa [7] 6, 13, 17, 90, 140, 164, 201
2 DDC [7] Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Cocaine addiction D03082 Benserazide [1] 6
3 DRD1 [6] Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Morphine addiction D00059 Levodopa [6] 6, 17, 90, 140, 164, 201
4 DRD1 [6] Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Morphine addiction D01044 Flupentixol [1] 97
5 DRD1 [6] Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Morphine addiction D07460 Apomorphine [3] 5, 6, 7
6 DRD1 [6] Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Morphine addiction D07870 Dopamine [4] 6, 7, 74, 299
7 DRD1 [6] Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Morphine addiction D08339 Pergolide [1] 6
8 DRD1 [6] Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Morphine addiction D09886 Dexpramipexole [1] 2
9 DRD1 [6] Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Morphine addiction D11431 Tavapadon [1] 6
10 DRD1 [6] Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Morphine addiction D11839 Foslevodopa [1] 6
11 DRD2 [6] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction D00059 Levodopa [6] 6, 17, 90, 140, 164, 201
12 DRD2 [6] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction D00136 Haloperidol [1] 8
13 DRD2 [6] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction D00270 Chlorpromazine [1] 254
14 DRD2 [6] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction D00426 Risperidone [5] 8, 156, 179, 187, 206
15 DRD2 [6] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction D00454 Olanzapine [2] 2, 8
16 DRD2 [6] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction D00560 Pimozide [1] 2
17 DRD2 [6] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction D00726 Metoclopramide [2] 46, 51
18 DRD2 [6] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction D00987 Cabergoline [3] 6, 74, 75
19 DRD2 [6] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction D01044 Flupentixol [1] 97
20 DRD2 [6] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction D01164 Aripiprazole [2] 6, 206
21 DRD2 [6] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction D01226 Sulpiride [2] 6, 70
22 DRD2 [6] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction D01348 Terguride [2] 51, 86
23 DRD2 [6] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction D01448 Trifluoperazine [2] 283, 284
24 DRD2 [6] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction D01745 Domperidone [5] 6, 13, 17, 51, 230
25 DRD2 [6] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction D02666 Iloperidone [1] 6
26 DRD2 [6] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction D03165 Bromocriptine [2] 6, 74
27 DRD2 [6] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction D05575 Pramipexole [3] 2, 6, 20
28 DRD2 [6] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction D05768 Rotigotine [1] 6
29 DRD2 [6] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction D07305 Piribedil [1] 6
30 DRD2 [6] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction D07309 Melperone [1] 6
31 DRD2 [6] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction D07460 Apomorphine [3] 5, 6, 7
32 DRD2 [6] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction D07593 Buspirone [2] 6, 51
33 DRD2 [6] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction D07868 Domperidone [5] 6, 13, 17, 51, 230
34 DRD2 [6] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction D07870 Dopamine [4] 6, 7, 74, 299
35 DRD2 [6] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction D08132 Lisuride [2] 6, 86
36 DRD2 [6] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction D08339 Pergolide [1] 6
37 DRD2 [6] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction D08456 Quetiapine [2] 6, 13
38 DRD2 [6] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction D08489 Ropinirole [4] 2, 6, 74, 309
39 DRD2 [6] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction D08590 Tiapride [1] 8
40 DRD2 [6] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction D08636 Trifluoperazine [2] 283, 284
41 DRD2 [6] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction D09397 Pardoprunox [1] 6
42 DRD2 [6] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction D09886 Dexpramipexole [1] 2
43 DRD2 [6] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction D09953 Pridopidine [3] 2, 6, 8
44 DRD2 [6] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction D09997 Cariprazine [1] 21
45 DRD2 [6] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction D11839 Foslevodopa [1] 6
46 GRIA2 [11] Neuroactive ligand-receptor interaction, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
47 GRIA2 [11] Neuroactive ligand-receptor interaction, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
48 GRIA2 [11] Neuroactive ligand-receptor interaction, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D02696 Talampanel [2] 2, 6
49 GRIA2 [11] Neuroactive ligand-receptor interaction, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D08964 Perampanel [3] 2, 6, 144
50 GRIN1 [11] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
51 GRIN1 [11] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D03742 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
52 GRIN1 [11] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D07058 Acamprosate [2] 6, 206
53 GRIN1 [11] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D07283 Esketamine [3] 2, 4, 70
54 GRIN1 [11] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D07441 Amantadine [4] 6, 8, 13, 127
55 GRIN1 [11] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D08098 Ketamine [8] 2, 4, 6, 13, 70, 113, 156, 215
56 GRIN1 [11] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D08174 Memantine [8] 2, 6, 8, 13, 49, 127, 205, 206
57 GRIN1 [11] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D09917 Latrepirdine [1] 8
58 GRIN2A [12] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction, Systemic lupus erythematosus D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
59 GRIN2A [12] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction, Systemic lupus erythematosus D03742 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
60 GRIN2A [12] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction, Systemic lupus erythematosus D07058 Acamprosate [2] 6, 206
61 GRIN2A [12] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction, Systemic lupus erythematosus D07283 Esketamine [3] 2, 4, 70
62 GRIN2A [12] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction, Systemic lupus erythematosus D07441 Amantadine [4] 6, 8, 13, 127
63 GRIN2A [12] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction, Systemic lupus erythematosus D08098 Ketamine [8] 2, 4, 6, 13, 70, 113, 156, 215
64 GRIN2A [12] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction, Systemic lupus erythematosus D08174 Memantine [8] 2, 6, 8, 13, 49, 127, 205, 206
65 GRIN2A [12] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction, Systemic lupus erythematosus D09917 Latrepirdine [1] 8
66 GRIN2B [13] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction, Systemic lupus erythematosus D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
67 GRIN2B [13] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction, Systemic lupus erythematosus D03742 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
68 GRIN2B [13] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction, Systemic lupus erythematosus D07058 Acamprosate [2] 6, 206
69 GRIN2B [13] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction, Systemic lupus erythematosus D07283 Esketamine [3] 2, 4, 70
70 GRIN2B [13] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction, Systemic lupus erythematosus D07441 Amantadine [4] 6, 8, 13, 127
71 GRIN2B [13] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction, Systemic lupus erythematosus D08098 Ketamine [8] 2, 4, 6, 13, 70, 113, 156, 215
72 GRIN2B [13] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction, Systemic lupus erythematosus D08174 Memantine [8] 2, 6, 8, 13, 49, 127, 205, 206
73 GRIN2B [13] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction, Systemic lupus erythematosus D09917 Latrepirdine [1] 8
74 GRIN2C [8] Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
75 GRIN2C [8] Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D03742 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
76 GRIN2C [8] Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D07058 Acamprosate [2] 6, 206
77 GRIN2C [8] Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D07283 Esketamine [3] 2, 4, 70
78 GRIN2C [8] Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D07441 Amantadine [4] 6, 8, 13, 127
79 GRIN2C [8] Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D08098 Ketamine [8] 2, 4, 6, 13, 70, 113, 156, 215
80 GRIN2C [8] Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D08174 Memantine [8] 2, 6, 8, 13, 49, 127, 205, 206
81 GRIN2C [8] Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D09917 Latrepirdine [1] 8
82 GRIN2D [8] Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
83 GRIN2D [8] Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D03742 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
84 GRIN2D [8] Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D07058 Acamprosate [2] 6, 206
85 GRIN2D [8] Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D07283 Esketamine [3] 2, 4, 70
86 GRIN2D [8] Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D07441 Amantadine [4] 6, 8, 13, 127
87 GRIN2D [8] Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D08098 Ketamine [8] 2, 4, 6, 13, 70, 113, 156, 215
88 GRIN2D [8] Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D08174 Memantine [8] 2, 6, 8, 13, 49, 127, 205, 206
89 GRIN2D [8] Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Nicotine addiction D09917 Latrepirdine [1] 8
90 MAOA [11] Glycine, serine and threonine metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease, Cocaine addiction D02561 Moclobemide [1] 6
91 MAOA [11] Glycine, serine and threonine metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease, Cocaine addiction D02579 Iproniazid [1] 6
92 MAOA [11] Glycine, serine and threonine metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease, Cocaine addiction D05458 Phentermine [1] 97
93 MAOA [11] Glycine, serine and threonine metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease, Cocaine addiction D08349 Phenelzine [1] 6
94 MAOB [11] Glycine, serine and threonine metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease, Cocaine addiction D02579 Iproniazid [1] 6
95 MAOB [11] Glycine, serine and threonine metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease, Cocaine addiction D03731 Selegiline [1] 6
96 MAOB [11] Glycine, serine and threonine metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease, Cocaine addiction D05458 Phentermine [1] 97
97 MAOB [11] Glycine, serine and threonine metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease, Cocaine addiction D08349 Phenelzine [1] 6
98 MAOB [11] Glycine, serine and threonine metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease, Cocaine addiction D08469 Rasagiline [6] 2, 5, 6, 17, 58, 66
99 MAOB [11] Glycine, serine and threonine metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease, Cocaine addiction D10158 Safinamide [2] 6, 17
100 MAOB [11] Glycine, serine and threonine metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease, Cocaine addiction D10829 Rasagiline [6] 2, 5, 6, 17, 58, 66
101 NFKB1 [59] MAPK signaling pathway, Ras signaling pathway, NF-kappa B signaling pathway, HIF-1 signaling pathway, Sphingolipid signaling pathway, PI3K-Akt signaling pathway, Longevity regulating pathway, Osteoclast differentiation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, IL-17 signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, TNF signaling pathway, Neurotrophin signaling pathway, Prolactin signaling pathway, Relaxin signaling pathway, Insulin resistance, Non-alcoholic fatty liver disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Epithelial cell signaling in Helicobacter pylori infection, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Toxoplasmosis, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Transcriptional misregulation in cancer, Viral carcinogenesis, MicroRNAs in cancer, Pancreatic cancer, Prostate cancer, Small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Inflammatory bowel disease, Diabetic cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis D01146 Iguratimod [5] 46, 51, 53, 271, 300
102 RELA [59] MAPK signaling pathway, Ras signaling pathway, NF-kappa B signaling pathway, HIF-1 signaling pathway, Sphingolipid signaling pathway, Mitophagy - animal, PI3K-Akt signaling pathway, Longevity regulating pathway, Osteoclast differentiation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, IL-17 signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, TNF signaling pathway, Neurotrophin signaling pathway, Prolactin signaling pathway, Relaxin signaling pathway, Insulin resistance, Non-alcoholic fatty liver disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Epithelial cell signaling in Helicobacter pylori infection, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Toxoplasmosis, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Transcriptional misregulation in cancer, Viral carcinogenesis, Pancreatic cancer, Prostate cancer, Small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Inflammatory bowel disease, Diabetic cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis D12181 Edasalonexent [1] 113
103 SLC6A3 [5] Synaptic vesicle cycle, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction D03215 Armodafinil [3] 6, 13, 84
104 SLC6A3 [5] Synaptic vesicle cycle, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction D04999 Methylphenidate [7] 6, 13, 34, 84, 113, 179, 206
105 SLC6A3 [5] Synaptic vesicle cycle, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction D05458 Phentermine [1] 97
106 SLC6A3 [5] Synaptic vesicle cycle, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction D07591 Bupropion [5] 8, 18, 21, 96, 171
107 SLC6A3 [5] Synaptic vesicle cycle, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction D08130 Lisdexamfetamine [1] 13
108 SLC18A2 [5] Synaptic vesicle cycle, Serotonergic synapse, Dopaminergic synapse, Parkinson disease, Cocaine addiction D08575 Tetrabenazine [1] 8
109 SLC18A2 [5] Synaptic vesicle cycle, Serotonergic synapse, Dopaminergic synapse, Parkinson disease, Cocaine addiction D10675 Valbenazine [1] 8
110 SLC18A2 [5] Synaptic vesicle cycle, Serotonergic synapse, Dopaminergic synapse, Parkinson disease, Cocaine addiction D10701 Deutetrabenazine [1] 8